Clinical Trial Update: Safety and Efficacy Study of Co-transfering of Mesenchymal Stem Cell and Regulatory T Cells in Treating End-stage Liver Disease [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial assessing co-transfer of mesenchymal stem cells and regulatory T cells for end-stage liver disease is in Phase 1/Phase 2 with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Cirrhosis

Drugs mentioned

• Mesenchymal stem cells (mesenchymal stem cells)
• Regulatory T Cells (regulatory T cells)

Snippet

Sponsor: Nanjing Medical University | Conditions: Liver Cirrhosis | Phase 1, Phase 2 | Status: UNKNOWN